FLASCO
- FDA approves nivolumab with ipilimumab for unresectable or metastatic hepatocellular carcinoma April 11, 2025On April 11, 2025, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab (Yervoy, Bristol Myers Squibb Company) for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC)
- FDA approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancer April 8, 2025On April 8, 2025, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab (Yervoy, Bristol Myers Squibb Company) for adult and pediatric patients 12 years of age and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC). The FDA also converted the accelerated...
- FDA approves durvalumab for muscle invasive bladder cancer March 28, 2025On March 28, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent durvalumab as adjuvant treatment following radical cystectomy, for adults with muscle invasive bladder cancer (MIBC).
- FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication March 28, 2025On March 28, 2025, the Food and Drug Administration expanded the indication for lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) to include adults with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy and are considered appropriate to delay taxane-based chemotherapy.
- FDA approves cabozantinib for adults and pediatric patients 12 years of age and older with pNET and epNET March 26, 2025On March 26, 2025, the Food and Drug Administration approved cabozantinib (Cabometyx, Exelixis, Inc.) for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET) and well-differentiated extra-pancreatic neuroendocrine tumors (epNET).
- FLASCO Proudly Announces the Release of a New White Paper Providing Practical Guidance on Expanding Access to Innovative Cancer Therapies March 24, 2025FLASCO is pleased to share a new white paper exploring the transformative potential of bispecific antibodies (BsAbs) in lymphoma treatment. Developed by thought leaders from across Florida, the paper offers actionable recommendations for wider adoption across Florida. With demonstrated success in clinical trials, BsAbs represent a significant advancement in cancer care. The report highlights the...
- FDA approves pembrolizumab for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1) March 19, 2025On March 19, 2025, the Food and Drug Administration granted traditional approval to pembrolizumab (Keytruda, Merck) with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1).
- Social Determinants of Health in Florida March 5, 2025
- FDA Issues FY24 Drug Safety Priorities Report February 26, 2025CDER’s latest Drug Safety Priorities Fiscal Year 2024 report highlights the extensive work of its multidisciplinary teams, showcasing significant safety-related milestones and achievements. These efforts underscore CDER’s ongoing commitment to promote and protect public health by addressing potential medication risks and enhancing safety measures. The report highlights continuing initiatives to combat the overdose crisis, including...
- FLASCO to Host Two Premier Oncology Training Programs at Moffitt Cancer Center in March 2025 February 25, 2025Press Release by Kellie Jordan RIVERVIEW, FL – February 25, 2026 – The Florida Society of Clinical Oncology (FLASCO) is pleased to announce the return of two premier oncology training programs: Great Strides Together on March 8, 2025, and Rapid Integrations on March 9, 2025. These back-to-back educational initiatives will take place at Moffitt Cancer Center in Tampa, FL,...